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ABSTRACT
Receptor tyrosine kinases-based autocrine loops largely contribute to activate
the MAPK and PI3K/AKT pathways in melanoma. However, the molecular mechanisms
involved in generating these autocrine loops are still largely unknown. In the present
study, we examine the role of the transcription factor RUNX2 in the regulation of receptor
tyrosine kinase (RTK) expression in melanoma. We have demonstrated that RUNX2deficient melanoma cells display a significant decrease in three receptor tyrosine kinases,
EGFR, IGF-1R and PDGFRβ. In addition, we found co-expression of RUNX2 and another
RTK, AXL, in both melanoma cells and melanoma patient samples. We observed a decrease
in phosphoAKT2 (S474) and phosphoAKT (T308) levels when RUNX2 knock down resulted
in significant RTK down regulation. Finally, we showed a dramatic up regulation of RUNX2
expression with concomitant up-regulation of EGFR, IGF-1R and AXL in melanoma cells
resistant to the BRAF V600E inhibitor PLX4720. Taken together, our results strongly
suggest that RUNX2 might be a key player in RTK-based autocrine loops and a mediator
of resistance to BRAF V600E inhibitors involving RTK up regulation in melanoma.

a highly conserved 128 amino acid DNA binding/proteinprotein interaction domain called the Runt-homology
domain [1]. RUNX2 is a major determinant of osteoblast
differentiation and regulates chondrocyte proliferation,
differentiation and hypertrophy during endochondral

INTRODUCTION
The RUNX (Runt-related transcription factor) family
is comprised of three closely related transcription factors,
RUNX1, RUNX2 and RUNX3. These genes are defined by
www.impactjournals.com/oncotarget
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bone formation [2–5]. In addition, RUNX2 regulates
the expression of genes closely associated with tumor
progression, invasion and metastasis [1, 6–9] and has proangiogenic effects [10–13]. We were the first to demonstrate
that RUNX2 was overexpressed in human melanoma cells
as compared with normal human melanocytes and that
RUNX2 deficiency inhibited cell growth, migration and
invasion of human melanoma cells. In addition, we showed
that decreased RUNX2 expression was associated with a
reduction in the expression of FAK [14], implicated in cell
migration [9, 15] and melanoma metastasis [16–18].
Up-regulation of the expression of EGF-R,
PDGFRβ, AXL and IGF-1R in melanoma cells that have
developed resistance to BRAF V600E targeted therapy
[19–25] results in reactivation of the MAPK and the
PI3K/AKT pathways. These pathways are crucial not
only for tumor cell survival and proliferation, but also
for continued tumor cell migration and invasion [26–31].
However, the mechanisms contributing to high levels
of these RTKs in melanomas have not been elucidated
either in the context of progressing tumors or in acquired
resistance to BRAF V600E inhibitors.
An early analysis of the expression of growth factors
and their receptors in melanomas showed that EGF was
overexpressed as compared to melanocytes while EGFR
was expressed in both melanomas and melanocytes. This
suggests a role for EGF-EGFR-based autocrine signaling
in melanoma cells [32]. In favor of this role, treatment
with cetuximab, a monoclonal antibody targeting the
extracellular domain of EGFR, reduced the invasive ability
of melanoma cells. Furthermore, in 114 patients with
primary cutaneous melanomas, EGFR expression was found
to be associated with metastatic spread to sentinel lymph
nodes and the presence of EGFR polysomy was correlated
with thicker primary tumors [33]. FGF-FGFR -based
autocrine signaling was also suggested by overexpression of
FGF2, FGF5 and FGF8 and different isoforms of the FGF
receptors (FGFR1-4) in melanoma cells. In addition, it has
been shown that stimulation of FGF receptors enhances the
motility of melanoma cells [32, 34].
IGF1R activation was reported in a panel of
25 melanoma cell lines derived from primary and
metastatic lesions [35] and a comprehensive analysis
of RTK activation in human melanoma samples and
cell lines identified autocrine signaling through IGF-1R
[36]. Disruption of the direct interaction between Focal
Adhesion Kinase (FAK) and IGF-1R by the small molecule
compound INT2-31 inhibited melanoma xenograft growth
in association with reduced levels of pAKT (S473) [37]. A
study on uveal melanoma supports the role of exogenous
and endogenous IGF-1 and their interaction with IFG-1R in
the development of metastases in the liver, which is a major
site for IGF-1 production and the predominant metastatic
site in 70-90% of uveal melanoma [38]. The contribution
of IGF-1 to melanoma cell migration was shown to require
the activation of PI3K by IGF-1R [39].
www.impactjournals.com/oncotarget

AXL is activated in melanomas [35] and engaged
in an autocrine loop due to endogenous production
of its ligand Gas6 [40]. In addition, AXL promotes the
pro-migratory and pro-invasive behavior of melanoma cells
[35, 40] and resistance to the BRAF V600E inhibitor
PLX4720 [20]. These findings are reinforced in a more
recent study, which demonstrated an increased resistance
to BRAF and ERK inhibition in melanoma cells expressing
low levels of MITF (Microphthalmia-associated
transcription factor) and high levels of AXL. This study
also showed a reverse correlation between MITF and
receptor tyrosine kinases, including AXL [21]. This study
confirmed the negative correlation between MITF and
AXL in melanoma cells [40, 41]. Since loss of MITF is also
accompanied by increased invasiveness [21, 42], it supports
previous findings that a high level of AXL expression is
associated with a pro-invasive phenotype in melanoma.
The present study was designed to investigate the
relationship between RUNX2 and the expression of receptor
tyrosine kinases (RTKs) in melanoma. We demonstrated the
co-expression of RUNX2 with IGF-1R, EGF-R, PDGFRβ
and AXL using ShRNA RUNX2-expressing melanoma cells
and showed co-expression of RUNX2 with AXL in human
melanoma samples. Most importantly, we demonstrate for
the first time that melanoma cells resistant to the BRAF
V600E inhibitor PLX4720 had a significant increase in
RUNX2 expression associated with an increase in RTKs
expression and activation. In addition, melanoma cells with
reduced expression of RUNX2 had an increased sensitivity
to PLX4720. We suggest that RUNX2 may be a driver of
increased receptor-tyrosine kinase (RTK)-based autocrine
signaling in melanoma and a key player in resistance to
targeted therapies involving up regulation of different RTKs.

RESULTS
ShRNA-mediated depletion of RUNX2 reduces
RTKs expression
We previously demonstrated that knock down of
RUNX2 using RUNX2 shRNA lentiviral expression
vectors decreased melanoma cell migration and invasion.
These findings suggest a role for RUNX2 in the migration
and invasive ability of melanoma cells [14]. In order to
define potential mediators of the RUNX2-mediated effects
on migration and invasion, we generated 250 μg of proteins
from stable 1205LU melanoma cell lines expressing two
types of RUNX2 ShRNA; ShRUNX2-2 (targeting RUNX2
3′UTR) and ShRUNX2-3 (targeting the RUNX2 coding
sequence) as previously described [14]. We then performed
a quantitative analysis of proteins up- or down-regulated
in the RUNX2 knocked down 1205LU cells relative to
non-silencing ShRNA-expressing 1205LU cells using
mass spectrometry. As shown in Table 1, reduced levels of
the receptor tyrosine kinases IGF-1R, FGFR1, PDGFRβ,
and EGFR were detected in the RUNX2 knocked down
29690
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Table 1: Proteomics analysis of the ShRNA RUNX2-2- and ShRNA RUNX2-3-expressing 1205LU melanoma cells as
compared with non-silencing (NS) control 1205LU expressing cells
Receptor tyrosine kinase (RTK)

ShRUNX2-2 ShRNA /NS ShRNA ShRUNX2-3 ShRNA /NS ShRNA

IGF-1R

NC

0.83

FGFR1

0.71

0.71

PDGFRβ

0.85

0.83

EGFR

NC

0.81

The protein expression of the listed receptor tyrosine kinases is expressed as ratio between ShRNA RUNX2-2- or ShRNA
RUNX2-3-1205LU cells and NS-1205LU cells. PDGFRβ: Platelet-derived growth factor receptor, beta; EGFR: epidermal
growth factor receptor; FGFR1: fibroblast growth factor receptor 1; IGF-1R: insulin-like growth factor 1 receptor. NC: No
Change.

Figure 1: RUNX2 knock down results in reduced expression of RTKs. A. Lysates from melanoma cell lines were analyzed for the
expression of IGF-1R, FGFR1, PDGFRβ, EGFR and AXL. B. RUNX2 and RTKs levels in non-silencing ShRNA (NS), ShRUNX2-2 (Sh2)
and ShRUNX2-3 (Sh3) stable melanoma cell lines. C. Levels of pAKT(T308), pAKT1(S473), pAKT2(S474), AKT, pERK1/2, ERK1/2 and
Actin in non-silencing ShRNA (NS), ShRUNX2-2 (Sh2) and ShRUNX2-3 (Sh3) stable melanoma cell lines. D. Levels of RUNX2, FGFR1,
EGFR, AXL, IGF-1R, PDFGRβ, phosphorylated EGFR (Y1068) and phosphorylated AXL (Y702) in C8161 and C81-61 melanoma cell lines.
www.impactjournals.com/oncotarget
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1205LU melanoma cells as compared with the nonsilencing (control) ShRNA-expressing 1205LU cells.
Because IGF-1R, FGFR1, and EGFR have been shown
to play major roles in melanoma progression through
autocrine signaling [32, 34, 36], and EGF-R, PDGFRβ, and
IGF-1R have been implicated in resistance mechanisms
to BRAF V600E targeted therapies [19-22, 24, 25], we
were interested in validating these results. Therefore,
we compared other melanoma cell lines expressing nonsilencing ShRNA, ShRUNX2-2 or ShRUNX2-3 for the
expression of these RTKs.
In addition to these RTKs identified by mass
spectrometry, we were also interested in identifying other
potential RTKs co-regulated with RUNX2 using patient data.
Using the CBio Portal for cancer genomics (http://www.
cbioportal.org) [43, 44], we found that the receptor tyrosine
kinase AXL was co-expressed with RUNX2 (Pearson’s
correlation = 0.56) after analysis of 278 skin cutaneous
melanomas (TCGA provisional RNASeqV2 RSEM).
To determine which melanoma cell lines to use
for validation of the co-expression of RUNX2 and the
aforementioned RTKs, we analyzed the expression of these
receptors in a panel of melanoma cell lines. As shown
in Figure 1A, IGF-1R is expressed by all the melanoma
cell lines and FGFR1 is highly expressed in 7 out of the
9 analyzed melanoma cell lines. EGFR is significantly
expressed in melanoma cell lines with the exception of
one. AXL is expressed in 6 out of the 9 melanoma cell
lines tested, and PDGFRβ is expressed at high levels
in three cell lines and at lower levels or undetectable in
the others. The expression level of the different RTKs
seems independent of the stage of progression, when
we compare cells derived from vertical growth phase
(VGP) melanomas (WM793, WM278 or WM115) or
from metastases (WM9, WM16717, 1205LU, C8161 and
UACC903). We further chose three cell lines (1205LU,
C8161 and WM35) for which RUNX2 knock down using
ShRUNX2-2 and ShRUNX2-3 was pronounced to validate
the co-expression of RUNX2 and RTKs.
Immunoblot analysis of 1205LU cells expressing
non-silencing ShRNA, ShRUNX2-2 or ShRUNX2-3
showed reduced levels of IGF-1R and EGFR only in
ShRUNX2-3-expressing 1205LU cells exhibiting the
strongest RUNX2 knock down. The expression of
PDGFRβ showed a decrease in both ShRUNX2-2- and
ShRUNX2-3-expressing 1205LU cells as compared
with non-silencing ShRNA-expressing 1205LU control
cells (Figure 1B, left panel), in accordance with Table 1.
Therefore, three of the four RTKs that we found negatively
regulated in the RUNX2-knocked down 1205LU
melanoma cells by mass spectrometry were validated
by immunoblot analysis. The expression of IGF-1R
was reduced in ShRUNX2-3-expressing C8161 cells or
ShRUNX2-3-expressing WM35 cells, as compared with
non-silencing ShRNA-expressing C8161 control cells or

www.impactjournals.com/oncotarget

non-silencing ShRNA-expressing WM35 control cells
respectively. Thus, as described for 1205LU cells, we
observe a decrease in IGF-1R only in cells demonstrating
nearly complete RUNX2 knock down (Figure 1B,
middle and right panels). Like IGF-1R, AXL expression
is only reduced in ShRUNX2-3-expressing C8161 cells
as compared with non-silencing ShRNA-expressing
C8161 cells (Figure 1B, middle panel). EGFR expression
is diminished in WM35 expressing ShRUNX2-2 or
ShRUNX2-3 as compared with non-silencing ShRNAexpressing WM35 cells. The strongest reduction of
EGFR expression was observed in the ShRUNX2-3expressing WM35 cells exhibiting almost complete
RUNX2 knockdown (Figure 1B right panel). We did
not detect changes in the expression of FGFR1 in any
of the RUNX2-knocked down melanoma cell lines (data
not shown). These results altogether show that RUNX2
knock down has a negative effect on the expression of
selected RTKs, with IGF-1R being downregulated in three
melanoma cell lines exhibiting RUNX2 knock down and
EGFR in two out of three cell lines.
RTKs stimulation leads to activation of the RAS/
MAPK and PI3K/AKT pathways [45]. Activation of
the RAS/RAF/MEK cascade leads to ERK1 and ERK2
phosphorylation [46] at T202/Y204 and T185/Y187
respectively. After activation of PI3K and subsequent
conversion of PIP2 to PIP3, AKT binds to PIP3 at the
membrane allowing PDK1 to phosphorylate T308 leading
to partial activation of AKT. Phosphorylation of AKT at
S473 (AKT1) or S474 (AKT2) stimulates full activity
[47]. We were interested in analyzing whether reduction of
RTK expression resulted in inhibition of phosphorylation
of ERK and AKT in RUNX2 knocked down melanoma
cell lines. Since opposing effects of AKT1 and AKT2
were described in breast cancer cell migration, AKT1
suppressing invasion and AKT2 enhancing it [48], we
analyzed phosphorylation of AKT1 and AKT2, in addition
to T308 in the RUNX2 knocked down melanoma cell lines.
As shown in Figure 1C, 1205LU expressing ShRUNX2-3
demonstrated reduction of AKT phosphorylated at T308
as compared with the non-silencing controls. In addition,
in 1205LU melanoma cell lines expressing ShRUNX2-3,
phosphorylation of AKT2 at S474 was decreased as
compared with the non-silencing control-expressing
1205LU cells. No modulation of phosphoAKT1(S473)
was detected in 1205LU melanoma cells expressing
ShRUNX2-2 or ShRUNX2-3. By contrast, we did not
observe any decrease in pAKT(T308), pAKT1(S473) and
pAKT2(S474) levels in C8161 ShRUNX2-2 or C8161
ShRUNX2-3 as compared with C8161 expressing the nonsilencing control. This result could be explained by the
maintained expression of EGFR in C8161 cells expressing
ShRUNX2-2 or ShRUNX2-3. EGFR expression in those
lines could trigger phosphorylation/activation of AKT, as
well as phosphorylation/activation of ERK1/2 as observed
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U1 Adaptor oligonucleotides targeting RUNX2
inhibit RUNX2 and RTK expression

in Figure 1C. Furthermore, the reduced expression of
RUNX2 and RTKs in 1205LU expressing ShRUNX2-3 did
not result in reduced levels of pERK1/2 levels (Figure 1C).
1205LU melanoma cells carry the BRAF V600E
activating mutation responsible to maintain an activated
MAPK/ERK pathway, reflected in high levels of pERK1/2
[49]. Therefore, our results are in accordance with earlier
studies showing that the activation of the MAPK/ERK
pathway can be driven only by the BRAF activating
mutation, independently of RTKs activation.
To further analyze the co-expression of RUNX2 and
RTKs, we examined the expression of RTKs in C81-61 and
C8161 melanoma cell lines ([50]. The C81-61 cell line is
derived from a Vertical-Growth Phase Melanoma and the
C8161 cell line from a metastasis from the same patient.
As shown in Figure 1D, C81-61 cells had undetectable
levels of RUNX2, in contrast to C8161 cells. In addition,
FGFR1, EGFR, and AXL were expressed at high levels in
C8161 cells as compared to C81-61 cells (Figure 1D). We
are aware that C8161 and C81-61 cell lines might have
numerous genetic and epigenetics differences in addition
to the differential expression of RUNX2. However, it
indicates that AXL might be an important RTK regulated
by RUNX2, since we also found decreased levels of
this RTK in C8161 expressing ShRUNX2-3, which
induces the strongest RUNX2 knock down. In addition,
we found high levels of phosphorylated EGFR (Y1068)
and phosphorylated AXL (Y702) in C8161 melanoma
cells, in contrast to C81-61 melanoma cells. These results
suggest that these RTKs are not only up-regulated but also
activated in C8161 melanoma cells.

To confirm the ShRNA data, we used a second and
novel approach to target RUNX2 expression through a
new strategy. This strategy uses U1 Adaptors, a recently
discovered oligonucleotide-based-silencing technology
whose unique mechanism of action targets nuclear
pre-mRNA processing. A U1 Adaptor is a synthetic
oligonucleotide (28-33 nucleotides) containing a 5’ target
domain, which binds to the target pre-mRNA, and a 3’ U1
domain that binds to the 5’ end of the U1 small nuclear
RNA subunit of U1 snRNP. As a result of the tethering
of the U1 snRNP to the target pre-mRNA, maturation
is prevented and reduced levels of mature mRNA are
produced [51]. To deliver the U1 Adaptors to the cells, we
used a tumor-targeting dendrimer nanoparticle previously
described [52]. The dendrimer nanoparticle, known
as RGD-G5, contains the cyclic RGD pentapeptide,
a tumor targeting ligand, which specifically binds the
α5β3 splice variant of an integrin cell surface receptor
overexpressed in a wide variety of cancer cells. The
RGD targeting ligand was coupled to the generation 5
(G5) polypropyleneimine (PPI) dendrimer in a final 2:1
molar ratio to give RGD-G5. Previous studies showed
that RGD-G5 was active as a delivery vehicle [52]. Using
the RGD-G5 dendrimer to deliver the U1 Adaptors,
we screened 6 RUNX2-specific U1 Adaptors for their
ability to reduce levels of RUNX2 mRNA. For that
purpose, C8161 and 1205LU cells were incubated in the
presence of the preformed RGD-G5: RUNX2 U1 Adaptor
complexes, for 72 hours, and RNA was then extracted. The
6 RUNX2 U1 Adaptors are designated RA1, RA2, RA3,
RA4, RA5 and RA6 for RUNX2 Adaptors 1 through 6.
The control used is designated NC3wt, a U1 Adaptor,
which does not target any human gene, but can still bind
U1 snRNP through its U1 domain. As shown in Figure 3A,
real time PCR determined that RA2 Adaptor was the most
efficient in reducing RUNX2 mRNA levels in both C8161
and 1205LU melanoma cells, lowering RUNX2 mRNA
levels to less than 40% of those in the presence of the
control NC3wt. For C8161, RA5 and RA6 were efficient
in reducing to 40 and 60% of the control respectively. For
1205LU, RA1, RA3 and RA4 decreased RUNX2 levels
to about 60% of the control. For the next experiments, we
used RA2 and RA5 Adaptors for C8161 cells and RA2 and
RA4 Adaptors for 1205LU cells. As shown in Figure 3B,
RA2 and RA5 for C8161 cells and RA2 and RA4 for
1205LU cells decreased RUNX2 protein expression.
In order to determine whether decreased RUNX2
expression translated into reduced RUNX2 activity and
decreased RTK expression, we analyzed the expression of
FAK, IGF1R and AXL mRNA by qPCR after transfection
of C8161 cells with RA2 or RA5 Adaptors and 1205LU
cells with RA2 or RA4 Adaptors. We previously showed
that RUNX2 regulates the expression of the FAK protein

RUNX2 and AXL co-expression in melanoma
samples
The results presented in Figure 1 prompted us to
analyze the co-expression of RUNX2 and AXL in human
melanoma samples. First, analysis of 278 cutaneous
melanomas (TCGA provisional RNASeqV2 RSEM) using
the CBio Portal for cancer genomics [43, 44] indicated
that AXL was co-expressed with RUNX2 (Pearson’s
correlation = 0.56). To confirm the mRNA expression
results, we performed an immunohistochemical analysis
of RUNX2 and AXL in the same melanoma tissue
microarray (TMA). The slides used for RUNX2 and AXL
immunohistochemical staining were two serial sections
of the TMA. Figure 2 shows representative pictures of
RUNX2 and AXL immunostaining of 39 cores expressing
significant levels of RUNX2 and exhibiting strong diffuse
(Figure 2A), faint focal (Figure 2B) or no (Figure 2C)
AXL staining. Analysis of the 39 cores expressing RUNX2
showed that 7 had strong AXL staining, 23 had faint AXL
staining and 9 were negative for AXL (Figure 2D). These
results suggest the co-expression of RUNX2 and AXL
proteins in a significant number of human melanoma
lesions.
www.impactjournals.com/oncotarget
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in melanoma cells [14]. Therefore, we used FAK mRNA
as a control for RUNX2 loss of activity and confirmed a
reduction of FAK expression in melanoma cells transfected
with the selected Adaptors RA2 and RA5 for C8161
cells, and RA2 and RA4 for 1205LU cells (Figure 3C).
In addition, these results suggest that the effect of
RUNX2 on FAK occurs at the transcriptional level.
We further analyzed the effect of RUNX2 knock down
on the mRNA expression of two previously identified
RTKs, IGF-1R and AXL. Figure 3C shows that RA2 and
RA5 for C8161 and RA2 and RA4 for 1205LU decrease
AXL mRNA expression, demonstrating that the effect of
RUNX2 on AXL protein expression (Figure 1B) occurs
at the transcriptional level. We also found that RA2
and RA5 decrease IGF-1R mRNA expression in C8161
melanoma cells (Figure 3C) in contrast to RA2 and RA4,
which do not inhibit IGF1R mRNA expression in 1205LU
melanoma cells (data not shown). It is possible that the
effect of RUNX2 on IGF1R protein expression (Figure 1B)
does not occur at the transcriptional effect in 1205LU

melanoma cells. Alternatively, it is also conceivable that
a complete knock down of RUNX2 has to be achieved
in order to see an effect on IGF1R mRNA expression in
1205LU cells as suggested by Figure 1B. Altogether, these
studies demonstrate that RUNX2-specific U1 Adaptors
significantly decrease the mRNA and protein expression
of RUNX2 and mRNA expression of some of its targets
genes, FAK, AXL and IGF1R.

AKT activity is involved in RUNX2 and RTK
expression
1205LU cells expressing ShRUNX2-3 and
exhibiting a decrease in RUNX2, IGF-1R, EGFR
and PDGFRβ levels also demonstrated a reduction in
pAKT2 (S474) and pAKT (T308) levels. This suggests
that RUNX2 might play a role in maintaining activation
of the PI3K/AKT pathway through the regulation of
RTKs in some melanoma cells. Furthermore, several
studies suggested a functional cooperation of RUNX2

Figure 2: RUNX2 and AXL co-expression in melanoma samples. Representative pictures of strong A., faint B. and negative C.

AXL staining in RUNX2-expressing melanoma cores from a melanoma tissue microarray. RUNX2 staining (Chromogenic detection using
red) in on the left panel, corresponding microscopic view of AXL staining (Chromogenic detection using DAB, brown) is on the right
panel. D. Expression levels of RUNX2 and AXL in the 39 RUNX2-expressing melanoma samples analyzed. The Y axis shows quantitative
Effective Staining Intensity (ESI; [71]) of RUNX2 in melanoma patient samples. The X axis expresses qualitative analysis of AXL staining
defined as strong, faint and negative. The scale bar represents 50 μm.
www.impactjournals.com/oncotarget
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and the PI3K/AKT pathway as a driving force for tumor
progression in different cancer types [8]. This functional
interaction led us to hypothesize that AKT activity
could also play a role in maintaining RUNX2 levels in
melanoma cells. To test this hypothesis we used MK2206,
an allosteric AKT inhibitor [53]. 1205LU and C8161
melanoma cells were treated with 10 μM MK2206 for
24 and 48 hours or for 16 and 36 hours respectively. As

shown in Figures 4A and 4B, treatment with MK2206
decreased levels of pAKT (S473) as expected for both
lines while levels of AKT were unchanged. 1205LU
melanoma cells exhibited reduced levels of RUNX2
expression at the two time points and a parallel decrease
in EGFR and AXL expression. C8161 exhibited a decrease
in RUNX2 expression at the 36-hour time point, with a
parallel decrease in EGFR and AXL expression. At the

Figure 3: U1 Adaptor oligonucleotides targeting RUNX2 inhibit RUNX2 and RTK expression. A. Expression of RUNX2

mRNA 72 hours after transfection of C8161 and 1205LU melanoma cell lines with the complexes, containing the dendrimer nanoparticle
RGD-G5 and each of the 6 RUNX2 specific U1 Adaptors, named RA1, RA2, RA3, RA4, RA5 and RA6 (RA for RUNX2 Adaptor). This
experiment, done in triplicate, is representative of three independent experiments. Results are expressed as % of relative RUNX2 mRNA
normalized to the control NC3wt +/- SEM. B. Immunoblot analysis of RUNX2 expression 72 hours after transfection of C8161 and
1205LU melanoma cell lines with the complexes, containing the dendrimer nanoparticle RGD-G5 and two selected RUNX2 specific U1
Adaptors (RA2 and RA5 for C8161, RA2 and RA4 for 1205LU). C. Expression of FAK, IGF-1R and AXL 72 hours after transfection of
C8161 cells with the RGD-G5-RA2 and RGD-G5-RA5 complexes and 72 hours after transfection of 1205LU cells with the RGD-G5RA2 and RGD-G5-RA4 complexes. The samples were analyzed in quadruplicate. This experiment is representative of three independent
experiments. Results are expressed as % of relative FAK, IGF1R or AXL mRNA normalized to the control NC3wt +/- SEM. * indicates p
< 0.05, ** indicate p < 0.01 and *** indicate p < 0.001 compared with NC3wt based on Student’s t-test.
www.impactjournals.com/oncotarget
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16-hour time point, C8161 cells showed a decrease in
AXL expression while RUNX2 levels were unchanged.
This data suggests that MK2206 effect on AXL expression
could be RUNX2 dependent or RUNX2 independent.

isoforms, as shown in Figure 5B. In accordance with
the TCGA data analysis, isoform 1 is expressed at lower
level than isoforms 2 and 3, which often appear together
as a thicker band (Figure 5B). Experiments presented on
Figures 1, 3 and 4 mainly showed isoforms 2 and/or 3
because of the low expression of isoform 1 as compared
with the other two isoforms. The experiments presented in
Figure 5C (see below) show the appearance of isoform 1
at higher levels.

RUNX2 isoforms 1, 2 and 3 are expressed at
varying levels in melanoma cells
We previously published the expression of RUNX2
in melanoma cell lines and RUNX2 appeared as a single
band on low exposure [14]. However, three main RUNX2
isoforms are produced through alternative splicing.
Isoform 1 (identifier Q13950-1) is the chosen canonical
sequence and the longest isoform. Isoform 2 (identifier
Q13950-2) has a different N terminal domain as compared
with isoform 1: 1-19: MASNSLFSTVTPCQQNFFW →
MRIPV. Isoform 2 is shorter than isoform 1. Isoform 3
(identifier Q13950-3) differs from isoform 1 by an internal
deletion for which amino acids 341-362 are missing. To
analyze the presence and expression of RUNX2 isoforms
in human tumors, we downloaded isoform expression
data from 471 samples from the TCGA-SKCM cohort.
Figure 5A shows the distribution of normalized expression
values of the three isoforms in this set (histogram, logtransformed expression values on the x-axis). Isoforms 2
and 3 are expressed in the cohort, while isoform 1 is mostly
not present. Isoforms 2 and 3 are expressed together with
a correlation of 0.79 (p<1.0e-100). Using a monoclonal
antibody raised against a synthetic peptide surrounding
A273 of human RUNX2 we were able to detect the three

Increased expression of RUNX2 isoforms in
melanoma cells resistant to BRAF V600E
inhibition
The up-regulation of EGF-R, PDGFRβ, AXL
and IGF-1R expression/activity plays a crucial role in
resistance mechanisms to targeted therapies using BRAF
V600E inhibitors [19-22, 24, 25]. Since we showed coregulation of RUNX2 and those RTKs, we postulated
that resistance to BRAF V600E inhibition could be
associated with an increase in RUNX2 expression. In
the first set of experiments, 1205LU melanoma cells
were treated with the BRAF V600E inhibitor PLX4720
in vitro and clones resistant to PLX4720 were selected
and expanded. Two clones resistant to 0.5 μM, three
clones to 3 μM and one clone to 5 μM PLX4720 were
analyzed for RUNX2 expression. As shown in Figure
5C (low exposure), two out of three clones resistant to
3 μM PLX4720 (clones 1 and 3), exhibited increased
level of RUNX2 isoforms 2/3, while an increase in

Figure 4: AKT activity is involved in RUNX2 and RTK expression. 1205LU A. and C8161 B. melanoma cell lines were treated
with vehicle (DMSO, (D)) or 10 μM MK2206 (MK) for the indicated times. Lysates were analyzed for the expression of pAKT, AKT,
RUNX2, EGFR, AXL and Actin.
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isoform 1 was observed in all but one clone resistant to
PLX4720. All the clones expressing RUNX2 isoform 1
showed increased levels of EGFR and IGF-1R, while
we found increased AXL expression in clones 1 and
3 up-regulating RUNX2 isoforms 2/3 in addition to
isoform 1. We further analyzed four of the six 1205LU
clones resistant to PLX4720 (clones 1,4, 5 and 6) for
the levels of phosphorylated/activated EGFR and IGF1R. We demonstrate increased expression of pEGFR
(Y1068) and pIGF-1R (Y1135/1136) in the four clones
as compared with the parental 1205LU melanoma cells
(Figure 5D). In addition, we show constitutive ERK1/2
and AKT (S473 and T308) phosphorylation in those
four PLX4720 resistant clones (Figure 5E). Therefore,
our results show an increase in RUNX2 levels and an
associated increase in RTK levels and activation in
1205LU clones resistant to PLX4720.

In the second set of experiments we took advantage
of the existence of cell lines established from PLX4720resistant tumors (PRT) in Dr. A. Aplin’s laboratory
(Kimmel Cancer Center Philadelphia, PA) [54, 55].
Briefly, 1205LU xenograft tumors initially shrank in
the presence of PLX4720 and rapid regrowth occurred
associated with ERK1/2 reactivation [54, 55]. Five cell
lines established from the resistant tumors, PRT3, PRT4,
PRT6, PRT9 and PRT11 were treated with vehicle or 1
μM PLX4720 for 24 hours in vitro as previously described
[54]. As shown in Figure 6A, the expression of RUNX2
isoforms 2/3 was increased in the five PRT lines in the
presence of PLX4720. An increase of isoform 1 was
only observed in PLX4720-treated PRT3. These results
suggest that PLX4720-resistant cells developed in an
in vivo context can exhibit an increase in RUNX2 levels
when reexposed to PLX4720 in vitro. These findings

Figure 5: Increased expression of RUNX2 isoforms and RTKs in melanoma cells resistant to BRAF V600E inhibition.
A. An isoform level analysis of RUNX2 expression in 471 samples from the TCGA-SKCM (Skin Cutaneous Melanoma) cohort shows
expression of variants 2 and 3 in the cohort, while variant 1 is mostly absent. Shown is the distribution of log-transformed expression values
for each isoform (X axis) across the samples. Y axis: Number of samples. B. Expression of RUNX2 isoforms 1, 2 and 3 in melanoma cell
lines. C. Clones resistant to 3 μM (clones 1-3), 5μM ((clone 4) and 0.5 μM (clones 5 and 6) PLX4720 were analyzed for RUNX2, EGFR,
IGF-1R and AXL expression. P: Parental 1205LU melanoma cell line. D. Levels of pEGFR (Y1068) and pIGF-1R (Y1135/1136) in parental
1205LU melanoma cells (P) and clones 1, 4, 5 and 6 resistant to PLX4720. E. Levels of pERK1/2, pAKT (pan) (S473), pAKT (T308),
ERK1/2 and AKT in clones 1, 4, 5 and 6 resistant to PLX4720.
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Figure 6: A. Expression of RUNX2 and RTKs in melanoma cells rendered resistant to BRAF V600E inhibition in vivo.

Melanoma cell lines established from PLX4720-resistant 1205LU xenografts (PRT lines 3, 4, 6, 9 and 11) were incubated in the presence of
DMSO (D) or 1 μM PLX4720 (PLX) for 24 hours and RUNX2, AXL, IGF-1R and EGFR expression was analyzed. Low and high exposures
for IGF1R are shown. B. Patient data from a cohort containing samples from untreated tumors and tumors treated with Vemurafenib and
Dabrafenib respectively [56] were downloaded from GSE50509. Expression of RUNX2 transcripts 1, 2 and 3 in untreated and Vemurafenib
and Dabrafenib treated groups. P-values were calculated using a t-test between untreated and vemurafenib treated groups.” C. 1205LU
melanoma cells expressing non-silencing ShRNA (NS), ShRUNX2-2 (Sh2) or ShRUNX2-3 (Sh3) were treated with Vehicle (DMSO) or 10
μM PLX 4720 for 72 hours and viable cells were then counted. This experiment, done in triplicate, is representative of three independent
experiments. Results are expressed as % (cell numbers in the presence of PLX4720 / cell numbers in the presence of DMSO). *** indicate
p < 0.001 compared with NS.
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cells, which parallels the higher level of expression of
RUNX2 in C8161 cells; 3) the co-regulation of RUNX2
and AXL in a significant number of human melanoma
samples (7 out of 39 samples with positive RUNX2
staining had strong AXL staining); 4) The increase in
EGFR, IGF-1R and AXL expression in 1205LU clones
resistant to the BRAF V600E inhibitor PLX4720 in
association with dramatic RUNX2 up-regulation in 5 out
of 6 clones analyzed; 5) The increase in IGF-1R and AXL
expression in association with RUNX2 up-regulation in
three out of five PLX4720-Resistant Tumor (PRT)-derived
cell lines treated in vitro with PLX4720 as compared
with vehicle-treated PRT cells. Furthermore, our results
strongly suggest that RUNX2 might be a mediator of
resistance to BRAF V600E targeted therapy, involving
RTK up-regulation and activation in melanoma. A working
model based on our findings is presented in Figure 7.
Because RUNX2 expression and activity are
positively regulated by the PI3K and MAPK pathways [8],
it is necessary to explore the relationship between IGF1/IGF-1R and RUNX2. IGF-1 was shown to positively
regulate RUNX2 expression in endothelial cells (EC) [13]
and osteoblasts [58], and to stimulate RUNX2 activity
in EC [59] and osteoblasts [60]. In EC, IGF-1 regulates
RUNX2 DNA binding through sequential activation of
the PI3K/Pak1 and ERK1/2 signaling cascade [59], but
independently of AKT. Another mechanism of IGF-1mediated increase in RUNX2 activity has been proposed
in osteoblasts. The transcription factor FOXO1 physically
interacts with RUNX2 in osteoblastic cells and in COS-7
cells and inhibits RUNX2 binding to its cognate site within
the osteocalcin promoter. Upon IGF1/insulin binding to
their receptors, activation of the PI3K/AKT pathway leads
to phosphorylation and nuclear exclusion of FOXO1 and
reactivation of RUNX2 [60]. We speculate that similar
regulation of IGF-1 on RUNX2 expression and activity
could exist in melanoma cells, through the activation of
IGF-1R and subsequent stimulation of the PI3K and/or the
MAPK pathways resulting in RUNX2 positive regulation. If
such a system exists, the regulation of IGF-1R by RUNX2
shown in the present study would suggest the existence
of a positive feedback loop of RUNX2/IGF-1/IGF-1R
in melanoma cells, promoting melanoma migration and
invasion. Similarly, the positive regulation of AXL, EGFR
and PDGFRβ by RUNX2 could result in an activation of
these receptors in the presence of their ligands (provided by
melanoma cells or the melanoma cell microenvironment)
thereby promoting stimulation of the PI3K and MAPK
pathway and RUNX2 positive regulation (as shown in
Figure 7).
AXL belongs to the TAM (Tyro3, AXL, MER)
family of RTKs [61]. Real time PCR examination of 8
AXL-positive tumors demonstrated that MER and TYRO3
transcripts were barely detectable and immunoblot
analysis of representative melanoma cell lines confirmed
mutual exclusion of AXL and TYRO3 and frequent

would also suggest that RUNX2 might be involved in
acquired resistance. In parallel to the RUNX2 increase,
we observed an increase in IGF-1R expression in four
out of five PLX4720-treated PRT lines (PRT lines 3,
4, 9 and 11) and in AXL expression in three out of five
PLX4720-treated PRT lines (PRT lines 4, 9 and 11). High
endogenous EGFR expression in those PRT lines was not
further modulated in the presence of PLX4720.
To address the relevance of these findings in human
melanoma, patient data from a cohort containing samples
from untreated tumors and tumors treated with vemurafenib
and dabrafenib respectively [56] were downloaded from
GSE50509. The data was analyzed on probe level in order
to avoid low expressed variants to distort the evaluation.
Probes for all three transcript variants were represented on
the Illumina array. The expression of RUNX2 isoform 3
was significantly higher in vemurafenib treated patients
compared to the untreated group (p=0.0024, Student’s
T-test). The expression of isoform 2 was slightly increased
in this group (p=0.0882), while isoform 1 was not
significantly changed among the groups (Figure 6B). These
results showing the up-regulation of specific isoforms of
RUNX2 in melanoma lesions from patients treated with
Vemurafenib, suggest that chronic exposure to BRAF
V600E inhibitors (PLX4720/Vemurafenib) may favor
RUNX2 up-regulation and subsequent RTK up-regulation,
an important player in acquired resistance to these drugs.
To determine whether RUNX2 expression played
a role in sensitivity to PLX4720, we treated 1205LU
melanoma cells expressing non-silencing ShRNA,
ShRUNX2-2 or ShRUNX2-3 with 10 μM PLX4720 for
72 hours and counted viable cells. As shown in Figure 6C,
RUNX2 knock down resulted in an increased sensitivity
to PLX4720 as compared with control cells.

DISCUSSION
In late stage melanomas, receptor tyrosine kinasebased autocrine loops contribute to the activation of
pathways such as MAPK and PI3K/AKT [57]. However,
little is known about the molecular events involved in
the dysregulation of RTKs expression/activity. Our data
identifies a candidate for this dysregulation. We initially
demonstrated the over-expression of transcriptionally
active RUNX2 in melanoma cell lines and melanoma
samples as compared with primary melanocytes and
melanocytic nevi respectively. We also implicated RUNX2
as an important factor in melanoma migration and invasion
[14]. Our present study points to RUNX2 as a potential
regulator of AXL, EGFR, IGF-1R and PDGFRβ and to
a lesser extent FGFR1 expression. This conclusion is
based on: 1) the down regulation of AXL, EGFR, IGF-1R
and PDGFRβ in ShRUNX2 knocked down melanoma
cell lines or RUNX2-specific U1 Adaptors-transfected
melanoma cells. 2) The higher expression of FGFR1,
EGFR and AXL in C8161 cells as compared with C81-61
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co-expression of TYRO3 and MER [40]. Another study
analyzed active RTKs in melanoma cell lines through
measurement of their level of tyrosine phosphorylation
and found that AXL, TYRO3 and MER were among
the RTKs with the highest overall activation level. Coactivation of TYRO3 and MER was also frequently
observed in these melanoma cell lines [35]. TYRO3
has been identified as an upstream regulator of the
Microphthalmia-associated transcription factor (MITF).
TYRO3 induces MITF-M expression in a SOX10dependent manner in melanoma cells [62], while other
studies showed the anti-correlation between MITF and
AXL in melanoma cells [40, 41]. These results suggest
that AXL and TYRO3 might play different roles in
melanoma progression, perhaps in relationship with MITF
expression. Interestingly, eighteen AML1a (RUNX1)
binding sites have been predicted to exist in the TYRO3
promoter, according to DECODE (DECipherment Of
DNA Elements), a SABiosciences’ proprietary database
combining their Text Mining Application and data from
the UCSC Genome Browser. Therefore, a parallel can be
drawn between the regulation of AXL by RUNX2 and
the potential regulation of TYRO3 by RUNX1. However,
more studies are required to confirm the regulation of
TYRO3 by RUNX1, and to decipher the role of RUNX1
in melanoma cells, which is co-regulated with RUNX2
with a Pearson’s Correlation of 0.31 in cutaneous

melanoma (TCGA provisional, 278 samples) using CBio
Portal (http://www.cbioportal.org) [43, 44].
We show that when the five PRT lines derived from
the PLX4720-resistant 1205LU melanoma xenografts are
treated in vitro with PLX4720, all PRT lines exhibit an
increased RUNX2 expression (isoforms 2/3) as compared
with vehicle-treated cells. In addition, we demonstrate
an increase in IGF-1R expression in four out of the five
PLX4720-treated PRT lines, while AXL expression is
increased in three out of five PLX4720-treated PRT lines.
PRT lines 4, 9 and 11 show parallel increase in RUNX2,
IGF-1R and AXL (Figure 6A). The selective increase in
RUNX2 isoforms 2/3 observed in PLX4720-treated PRT
lines derived from PLX4720-resistant tumors (Figure 6A)
and in Vemurafenib-treated patients (Figure 6B) is in
apparent contradiction with the high expression of isoform
1 in all but one 1205LU clones developing resistance to
PLX4720 in vitro (Figure 5C). In 1205LU clones developing
resistance in vitro, two of the six clones expressed increased
levels of isoforms 2/3. The tumor microenvironment present
during the in vivo treatment with the BRAF V600E inhibitors
(PLX4720-treated xenografts and Vemurafenib-treated
patient tumors) but absent in clones developing PLX4720
resistance in vitro, likely plays a role in these differences in
the type of RUNX2 isoforms up-regulated.
Interestingly, PRT6 was shown to carry a HRAS
Q61K mutation; PRT3 was shown to express a previously

Figure 7: Working model for the role of RUNX2 in RTK-based autocrine loops and resistance to BRAF V600E targeted
therapy. RUNX2 regulates RTK expression by mechanisms yet to be defined. Treatment of melanoma cells with BRAF V600E inhibitors

(PLX4720, Vemurafenib) eventually results in up-regulation of RUNX2 and subsequent up-regulation of RTKs, implicated in resistance
to BRAF V600E targeted therapy, through increased proliferation, survival, migration and invasion. Reactivation of the oncogenic MAPK
pathway through RTK up-regulation compensates for the inhibition of BRAF V600E. Those RTKs also signal through the PI3K/AKT
pathway and AKT activation contributes to maintain high RUNX2 levels. This positive feedback loop contributes to drive progression of
resistant melanoma cells.
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unreported variant that splices exon 2 with exon 11 of BRAF
V600E; PRT4 was found to express a variant previously
reported from a patient sample that splices exon 1 with
exon 9 of BRAF V600E. Both PRT3 and PRT4 maintained
V600E positivity [54]. The BRAF V600E variants and the
HRAS mutation were sufficient for resistance to PLX4720
treatment. This study illustrates that from a single cell line,
multiple mechanisms of resistance could emerge [54].
Due to the heterogeneity of resistant tumors, these authors
proposed taking several biopsies from multiple sites for
molecular analysis [54]. Our data suggests that in addition
to examining RAS mutations and BRAF variants during
the molecular analysis of tumor samples, we should also
include the analysis of RTK up-regulation/activation, as it
participates in a significant number of acquired resistance
mechanisms, possibly in conjunction with RAS mutation
or the existence of V600E splicing variants.
Regarding resistance to RTK inhibition, we observed
that downregulation of IGF-1R and AXL in C8161
melanoma cells expressing ShRUNX2-3 (Figure 1B)
did not result in reduced AKT and ERK phosphorylation
(Figure 1C) but instead increased AKT phosphorylation.
It is possible that the increased activation of EGFR whose
expression was unchanged or expression/activation
of another RTK compensated for the reduction in IGF1R- and AXL-mediated signaling. Such a compensatory
mechanism has been described in non-small cell lung
cancer (NSCLC) cells: Treatment with the EGFR erlotinib
inhibitor induced heterodimerization of insulin-like
growth factor receptor/epidermal growth factor receptor,
activated IGF-1R and downstream signaling mediators,
which ultimately counteracted the antitumor action of
erlotinib in NSCLC cells [63]. These results support the
hypothesis that the reactivation of other RTKs (through
homo or heterodimerization) is likely to happen following
down regulation of one or two RTKs or their inhibition by
small molecules inhibitors.
We demonstrated that RUNX2 knock down
resulted in down regulation of FAK ([14] and Figure 3) in
addition to IGF-1R, EGFR, PDGFRβ and AXL decrease.
Interestingly, disruption of the protein interaction
between FAK and IGF-1R by a small molecule (INT231) induced apoptosis and cell cycle arrest, inhibited AKT
phosphorylation in vitro and in tumors, and decreased
growth of melanoma xenografts [37]. These results
suggest that targeting RUNX2 expression or activity might
induce similar effects by negatively affecting FAK-IGF1R interaction. In addition, the involvement of RUNX2
in the regulation of four different RTKs implicated in
melanoma progression and acquired resistance to BRAF
V600E inhibitors suggests that RUNX2 is a potential
therapeutic target in patients with melanoma. RUNX2
belongs to a class of proteins traditionally considered
undruggable. However, transcription factors have
become the focus of new targeting strategies: These new
strategies exploit the fact that transcription factor activity
www.impactjournals.com/oncotarget

is regulated at distinct levels and that we can interfere
with each of these levels, including specific binding to
cis-regulatory elements or homo- and hetero-dimerization
[64, 65]. There is increasing evidence that transcription
factors play oncogenic roles in melanoma and this has
driven efforts to develop new approaches to target this
class of proteins [66]. Targeting RUNX2 binding to cisregulatory elements and RUNX2 interaction with major
co-activators/transcription partners, such as SMADS [8,
67] are likely to open new avenues of therapy for patients
with melanoma.

MATERIALS AND METHODS
Cell lines
WM9, WM1617, WM793, WM278, and 1205LU
were kindly provided by Dr. M. Herlyn (Wistar Institute,
Philadelphia, PA, USA [49]). These lines were cultured in
MCDB153/L-15 (4/1 ratio) medium containing 2% FBS,
5 μg/ml Insulin and 1.7 mM Calcium Chloride. C8161 and
C81-61 melanoma cell lines were provided by Dr. Mary
Hendrix (Children’s Memorial Research Center, Chicago,
IL, USA [50] and were grown in D-MEM (Mediatech,
10-013-CV) containing 10% FBS. UACC903 and
UACC930 cells were provided by Dr. Jeffrey M. Trent
(Translational Genomics Research Center, Phoenix, AZ,
USA [68]) and were grown in RPMI1640 (Invitrogen,
11875) containing 10% FBS. WM115 and WM35
melanoma cell lines were purchased from ATCC
(American Type Culture Collection, Manassas, VA
20110, U.S.A). WM35 and WM115 [49] were grown in
MCDB153/L-15 (4/1 ratio) medium containing 2% FBS,
5 μg/ml Insulin and 1.7 mM Calcium Chloride. PLX4720
resistant clones were kindly provided by Dr S. Chen
(Rutgers University, Piscataway NJ). Briefly, 2-4 x 105
1205LU melanoma cells were plated in a 60 mm dish in
the presence of increasing concentrations of PLX4720
(from 0.1 to 5 μM). Resistant clones were then expanded
successively in 24-well plates, 35 and 60 mm dishes in
the presence of the respective concentrations of PLX4720.

Treatment with pharmacological agents
For MK2206 treatment, 1205LU and C8161
melanoma cell lines were treated with vehicle (DMSO)
or the allosteric AKT inhibitor, MK2206 (10 μM), for
24 and 48 hours and for 16 and 36 hours respectively.
Whole cell lysates were then prepared as described below
in the immunoblotting section. For PLX4720 treatment
of 1205LU melanoma cells expressing non-silencing
ShRNA, shRUNX2-2, or ShRUNX2-3, 105 cells were
seeded, treated the next day with 10 μM PLX4720 for
72 hours and then counted using a Vi-Cell counter.
For PLX4720 treatment of the PRT lines, 5x105 PRT
(PLX4720-Resistant Tumors) -derived cell lines (PRT
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lines 3, 4, 6, 9 and 11 [54]) were seeded on a 10 cm plate
and allowed to proliferate without drug for 72 hrs. Then
cells were then treated with vehicle (DMSO) or 1 μM
PLX4720 for 24 hrs, before protein extraction.

criteria: peptide log€ <-1.5, sum of reporter ion intensity
>4,000. Protein ratios were calculated using median value
of ratios of all peptides belonging to the same protein that
fits criteria described above.

Immunoblotting

Proteomics analysis of ShRNA RUNX2expressing melanoma cells using iTRAQ protocol

Cells were harvested, washed with PBS, and
lysed with cell lysis buffer in the presence of protease
and phosphatase inhibitors (Roche) as previously
described [14]. Equal amounts of protein were separated
on polyacrylamide gel electrophoresis and transferred
onto nitrocellulose membrane, and immunoblots were
analyzed using antibodies against RUNX2, GAPDH,
FAK, EGFR, PDGFRβ, FGFR1, IGF-1R, pAKT1 (S473),
pAKT2 (S474), pAKT (T308), phosphop44/42 MAPK
(ERK1/2) (T202/Y204), pEGFR (Y1068), pAXL (Y702)
from Cell Signaling (Danvers, MA), AXL from R&D
systems (Minneapolis, MN), pIGF-1R (Y1135/1136) from
ThermoFisher Scientific (Rockford, IL) and Actin (Sigma
Aldrich, St. Louis, MO).

Samples were lysed as previously described [14].
The protein samples (120 ug) were run into a Novex BisTris 10% gel as gel plugs and digested with trypsin using
standard protocol. The digested peptides were washed
with methanol and labeled with iTRAQ reagent (Sciex)
using manufacturer’s recommended protocol and then
combined.
High-pH Reverse phase HPLCs were used for
peptide fractionation using Gilson 300 series. Samples
were solubilized in 200 μl of 20 mM ammonium formate
(pH10), and injected onto an Xbridge column (Waters,
C18 3.5 μm 2.1X150 mm) using a linear gradient of
1%B/min from 2-45% of B (buffer A: 20 mM ammonium
formate, pH 10, B: 20 mM ammonium formate in 90%
acetonitrile, pH10). 1min fractions were collected and
speed vac dried.
Selected fractions were either combined or directly
analyzed by LC-MS/MS. 5μl /12.5 μl of fractionated
samples were analyzed by nanoLC-MS/MS using a RSLC
system (Dionex, Sunnyvale CA) interfaced with a LTQ
Orbitrap Velos (ThermoFisher, San Jose, CA). Samples
were loaded onto a self-packed 100μm x 2cm trap packed
with Magic C18AQ, 5μm 200 A (Michrom Bioresources
Inc, Aubum, CA) and washed with Buffer A (0.2% formic
acid) for 5 min with a flow rate of 10ul/min. The trap was
brought in-line with the homemade analytical column
(Magic C18AQ, 3μm 200 A, 75 μm x 50cm) and peptides
fractionated at 300 nL/min with a multi-stepped gradient
(4 to 15% Buffer B (0.16% formic acid 80% acetonitrile)
in 25 min and 15-25%B in 65 min and 25-50%B in 55
min). Mass spectrometry data was acquired using a datadependent acquisition procedure with a cyclic series of a
full scan acquired in Orbitrap with resolution of 60,000
followed by MSMS scans (HCD 38% of collision energy)
of 10 most intense ions with a repeat count of two and the
dynamic exclusion duration of 60 sec.
The LC-MSMS data was searched against the human
Ensembl database using an in house version of X!tendem
(SLEDGEHAMMER (2013.09.01),thegpm.org) with
carbamidomethylation on cysteine and iTRAQ labeling on
lysine and N-terminus of the peptide as fixed modification
and oxidation of methionine as variable modification using
a 10 ppm precursor ion tolerance and a 20 ppm fragment
ion tolerance. Intensity of iTRAQ reporter ions of each
spectrum was extracted using an in-house perl script
corrected for isotope cross-over using values supplied by
the manufacturer. The ratio was normalized using median
intensity ratio of all identified spectra that fit certain
www.impactjournals.com/oncotarget

Detection of AXL by immunohistochemistry
The human melanoma tissue microarray (TMA
number ME1004A) was purchased from US Biomax,
Inc. (Rockville, MD, USA). The melanoma TMA was
deparaffinized and antigen retrieval was performed using
extended CC1 treatment (Cell Conditioning Solution,
Ventana Medical Systems, Oro Valley, AZ). The goat
polyclonal antibody for AXL (R&D) was applied
and incubated at 37°C for 1 or 2 hours. Donkey antigoat secondary antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA) was then applied and
incubated at 37°C for 60 min, followed by chromogenic
detection using the DAB Map kit (Ventana Medical
Systems, Oro Valley, AZ). Slides were counterstained
with Hematoxylin and dehydrated and cleared before
coverslipping from Xylene. RUNX2 staining was done as
previously described [14].

Analysis of IHC staining
Tissue microarray specimens were imaged using
Trestle® whole slide imaging system under a 20x
objective. Custom whole slide visualization software
[69] developed at Center for Biomedical Imaging &
Informatics, Rutgers Cancer Institute of Pathology, was
used to display high-resolution, synchronized, side-byside views of corresponding TMA cores stained with
RUNX2 and AXL and a board-certified pathologist
examined tissue composition and staining intensity
at each TMA core location. Quantification of RUNX2
expression was previously reported [14]. Due to the
presence of non-melanoma cells staining and melanin
in the specimen, evaluation of AXL expression level
was conducted in a semi-quantitative manner. A board29702
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RNA extraction, RT-PCR and real-time PCR for
the experiments with U1 Adaptors

certified pathologist closely examined side-by-side
views of each AXL stained TMA core with its RUNX2
staining counterpart, and determined co-localizing AXL
expression level in melanoma cells to be “Strong”,
“Faint” or “Negative”.

Total RNA was extracted from transfected cells
using Trizol reagent (Invitrogen,Carlsbad, CA) and further
purified using NucleoSpin RNA kit (Macherey-Nagel,
Germany) according to the manufacturer’s instructions.
500 ng of total RNA was used for cDNA synthesis with
random hexamers using high capacity cDNA reverse
transcription kit (Applied Biosystems) according to the
manufacturer’s instructions. For RT-PCR amplifications
SYBR Green PCR master mix (Applied Biosystems) was
prepared with appropriate forward and reverse primers
and cDNA according to the manufacturer’s instructions.
The thermal cycling conditions were composed of an
initial denaturation step at 95°C for 10 min, 40 cycles
at 95°C for 30s, 55°C for 30s and 72°C for 30s with a
Mx3000P (stratagene). A melting curve was generated by
slowly increasing (0.1°C/s) the temperature from 60°C to
95°C, while the fluorescence was measured. Reactions
were run in duplicates in three independent experiments.
The housekeeping gene GAPDH was used as an internal
control for normalization. The fold change in the mRNA
levels in the RUNX2 U1 Adaptor-transfected cells was
analyzed by comparing to RGD-G5 transfected cells
using the 2 -ΔΔCT method previously described [70]. The
results are presented as percentage of RUNX2 remaining
by setting the value from RGD-G5 transfected cells to
100%. Data from qPCR experiments are presented as the
average ± standard error of the mean. Statistical analysis
was performed by Student’s t test and P values < 0.05
were considered statistically significant.

RUNX2 knock down using ShRNA
We used two different human RUNX2 ShRNA,
targeting either the coding sequence (ShRUNX2-3) or
the 3’UTR (ShRUNX2-2), in the pGIPZ lentiviral vector.
The mature senses were CCAGCTGCATCCTATTTAA
for ShRUNX2-2 and ACAAGGACAGAGTCAGATT
for
ShRUNX2-3.
The
mature
sense
was
ATCTCGCTTGGGCGAGAGTAAG for the non-silencing
control. This sequence does not match any known
mammalian gene (has at least 3 or more mismatches
against any gene as determined via nucleotide alignment/
BLAST of 22mer sense sequence). 80-90 % confluent
293 amphotropic cells were transfected with 10 μg of
non-silencing control or shRUNX2 plasmid and 4 μg of
PREV (pcmv-dR8.2 dvpr) plasmid using Lipofectamine
2000 (Invitrogen, Carlsbad, CA). 48 hours following
transfection, the supernatant media was filtered through
a 0.4uM filter for infection. Melanoma cell lines C8161,
WM35 and 1205LU were seeded at a density of 0.2 x 106
cells/ 6 well plate 24 hours prior to the infection. The cells
were then infected with 1 ml viral particles and 8ug/ml
polybrene and after 6 hours, 1ml fresh media was added
and incubated for overnight. The following day, cells
were incubated with 2 ml fresh media followed by stable
selection with 3 μg/ml Puromycin for 1 to 2 weeks.

RUNX2 mRNA targeting using anti-RUNX2 U1
Adaptors

Patient data analysis
Level 3 RNASeqV2 isoform expression data
from 471 samples in the TCGA-SKCM cohort were
downloaded and RUNX2 isoform probes corresponding
to the three variants were selected. The rsem normalized
values were log-transformed (log2(data+1)) and a
histogram was generated using the MATLAB routine hist.
Patient data from a cohort containing samples from
untreated tumors and tumors treated with vemurafenib
and dabrafenib respectively [56] were downloaded from
GSE50509. The data was downloaded in the pre-normalized
form, and probes for RUNX2 were selected. We used the
box plot routine (MATLAB) to plot the three different
treatment groups for all probes individually. The plot shows
data between 25th and 75th percentile within the blue boxes
and the median as red line in each group. Whiskers indicate
the 5th and 95th percentiles and outliers are indicated as
data points in red. P-values were calculated using a t-test
between untreated and vemurafenib treated groups.”

The panel of anti-RUNX2 U1 Adaptors was
designed by and then purchased from Silagene Inc.
(Hillsborough, NJ). The RGD-G5 dendrimer was prepared
as previously described [52]. The 1205LU and C8161 cells
were plated at 200,000 cells per well in a 6 well plate.
Transfection of anti-RUNX2 U1 Adaptors or control U1
Adaptors in complex with RGD-G5 dendrimers was done
as follows: for a 6-well plate, a 0.2 ml transfection mix
containing 20mM HEPES buffer pH 7.4 in water was
prepared containing 200nM U1 Adaptor and 1500nM
RGD-G5 dendrimer, and the solution gently mixed. The
RGD-G5:anti-RUNX2 U1 Adaptors complexes were
then added to cells that had been overlaid with 1.8 ml of
fresh growth media giving a final concentration of 20nM
U1 Adaptor and 150nM RGD-G5 dendrimer. After 72
h, either total RNA was extracted for qPCR or protein
extracted for Western blotting.
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